Optimized Carbohydrate-Based Nanogel Formulation to Sensitize Hypoxic Tumors.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Solid tumors often exhibit poor vascularization, leading to hypoxia.
• Tumor hypoxia promotes cancer progression, invasion, metastasis, and treatment resistance.

Purpose of the Study:

• To develop and evaluate a hypoxia-directed nanosensitizer for targeted cancer therapy.
• To encapsulate a hypoxia-activated prodrug (HAP) into a novel nanogel for improved delivery and efficacy.

Main Methods:

• A carbohydrate-based nanogel encapsulating iodoazomycin arabinofuranoside (IAZA), a HAP, was synthesized.
• The nanogel formulation (nanoIAZA) was characterized for loading capacity, release kinetics, and in vitro/in vivo efficacy.
• Cytotoxicity, radiosensitization, and systemic toxicity were assessed in cancer cell lines and mouse models.

Main Results:

• The nanogel achieved high IAZA loading (80-88%) with controlled release over 50 hours.
• nanoIAZA demonstrated superior in vitro hypoxia-selective cytotoxicity and radiosensitization compared to free IAZA.
• In vivo studies showed significant tumor growth inhibition and improved survival in FaDu xenografts with no observed toxicity.

Conclusions:

• The developed nanoIAZA formulation is a promising hypoxia-targeted theranostic agent.
• This nanosensitizer offers enhanced anti-tumor efficacy and improved tumor regression for hypoxic cancers.
• The nanogel platform facilitates selective drug delivery, overcoming limitations of conventional therapies.